Aarkstore - Complete 2013-14 Induced Pluripotent Stem Cell (iPSC) Industry Report - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Aarkstore - Complete 2013-14 Induced Pluripotent Stem Cell (iPSC) Industry Report

Description:

Stem cell research and experimentation has been in process for well over five decades, as stem cells have the unique ability to divide and replicate repeatedly. In addition, their “unspecialized” nature allows them to differentiate into a wide variety of specialized cell types. – PowerPoint PPT presentation

Number of Views:29

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Aarkstore - Complete 2013-14 Induced Pluripotent Stem Cell (iPSC) Industry Report


1
Category Healthcare
Complete 2013-14 Induced Pluripotent Stem Cell
(iPSC) Industry Report
  • Browse Complete Report -
  • http//www.aarkstore.com/healthcare/51108/Complete
    -2013-14-Induced-Pluripotent-Stem-Cell-iPSC-Indust
    ry-Report

f
2
f
Executive Summary
Stem cell research and experimentation has been
in process for well over five decades, as stem
cells have the unique ability to divide and
replicate repeatedly. In addition, their
unspecialized nature allows them to
differentiate into a wide variety of specialized
cell types. The possibilities arising from these
characteristics have caused great commercial
interest, with potential applications ranging
from the use of stem cells in reversal or
treatment of disease, to targeted cell therapy,
tissue regeneration, pharmacological testing on
cell-specific tissues, and more. Diseases such as
Huntingtons Chorea, Parkinsons Disease, and
spinal cord injuries are examples of clinical
applications in which stem cells could offer
benefits in halting or even reversing
damage. Traditionally, scientists have worked
with both embryonic and adult stem cells as
research tools. While the appeal of embryonic
cells has been their ability to differentiate
into any type of cell, there has been significant
ethical, moral and spiritual controversy
surrounding their use for research purposes.
Although some adult stem cells do have
differentiation capacity, it is often limited in
nature, which creates narrow options for use.
Thus, induced pluripotent stem cells represent a
promising combination of adult and embryonic stem
cell characteristics.
3
f
Executive Summary
Discovery Groundbreaking experimentation in
2006 led to the introduction of induced
pluripotent stem cells (iPSC). These are adult
cells which are isolated and then transformed
into embryonic-like stem cells through the
manipulation of gene expression, as well as other
methods. Research and experimentation using mouse
cells at Kyoto University in Japan was the first
instance in which there was successful generation
of the iPSC. In 2007, a series of follow-up
experiments were done at Kyoto University in
which human adult cells were transformed into
iPSC cells. While there has been continued
excitement at the prospect of what such
artificially re-manufactured cells could
contribute to medical advances, there have also
been issues along the way. By 2010, there were a
number of private companies that were ready to
capitalize on the breakthrough technology that
iPSCs represent. One such company, Advanced Cell
Technology in Worcester, Massachusetts,
discovered several problematic issues while
conducting experiments for the purpose of
applying for U.S. Food and Drug Administration
approval to use iPSCs in therapeutic
applications. Concerns such as premature cell
death, mutation into cancer cells, and low
proliferation rates were some of the problems
that surfaced.
4
f
Executive Summary

Furthermore, the past twelve months have been a
time of massive change for the industry. 2013 was
the first year in which clinical research
involving transplant of iPSCs into humans was
initiated, with Masayo Takahashi of the RIKEN
Center in Japan investigating the safety of
iPSC-derived cell sheets in patients with macular
degeneration. In another landmark event, Cellular
Dynamics International (CDI) went public in July
2013 with a offering that raised 43 million
dollars for the company, securing the companys
position as the global leader in producing
high-quality human iPSCs and differentiated cells
in industrial quantities. In March of 2013,
Celullar Dynamics International and the Coriell
Institute for Medical Research announced
receiving multi-million dollars grants from the
California Institute for Regenerative Medicine
(CIRM) for the creation of iPSC lines from 3,000
healthy and diseased donors, a result that will
create the worlds largest human iPSC bank. 2013
represents a major year for advances in clinical
research applications, production and
differentiation technologies, and biobanking of
iPSCs. It is clear that iPSCs are a vital
research trend within the scientific community.
5
Table of Content
  1. ABSTRACT II. BACKGROUND A. Definition B.
    Discovery C. Advantages Disadvantages III.
    TIMELINE A. Production of iPSCs (Key Events) B.
    Full Timeline of Events IV. RESEARCH
    APPLICATIONS A. Pharmaco-Toxicological
    Screening B. Disease Modeling C. Autologous Cell
    Transplantation D. Breakdown of iPSC Research, By
    Applied Research Application

6
f
Table of Content
V. CHARACTERIZATION OF iPSC RESEARCH ADVANCES A.
Methods of Making iPSCs Comparison of Methods
by Downstream Application B. Summary of iPSC
Derivation Methods, by Cell Type C. Diseases in
Which iSPCs Have Been Derived from Patients VI.
COMPANIES SELLING iPSC RESEARCH PRODUCTS A.
Complete List of Companies B. Rate of Entrants by
Year VII. TYPES OF iPSC RESEARCH PRODUCTS A.
Stem Cell Product Categories B. iPSC Market Share
Breakdown, By Product Area
7
f
Table of Content
VIII. COMPANIES DEVELOPING iPSC THERAPIES A.
Commerical Entities 1. Cellular Dynamics
International (CDI) 2. Fate Therapeutic 3.
iPerian  4. ViaCyte  5. Advanced Cell Technology
(ACT)  B. Non-Commercial Organizations Developing
iPSC Therapies IX. STRATEGIC COLLABORATIONS FOR
DEVELOPMENT OF iPSC PRODUCTS A. Life
Technologies (Recently Acquired by Thermo Fisher
Scientific) B. Lonza Group AG C. EMD Millipore D.
Sigma Aldrich E. Roslin Cells, Ltd. F. ArunA
Biomedical G. CeeTox and Cellular Dynamics
8
f
Table of Content
X. MARKET TREND ANALYSIS A. Clinical Trials B.
Grant Analysis 1. Historical Analysis 2. Future
5-Year Projection C. Patent Analysis D.
Scientific Publication Analysis 1. Historical
Data  2. Future 5-Year Projections 3. Comparison
of iPSC Research Frequency, Relative to Other
Cell Types E. Search Phrase Analysis 1. Google
News Search Results for iPSC Terms 2. iPSC
Product Launches, by Year F. Geographical
Analysis Domestic vs. International Status 1.
Number of iPSC Labs, by Region of World  2.
Percent of Total iPSC-Specific Research Funding,
by Region of World G. Additional Sources of iPSC
Research Funding 
9
f
Related Reports
Epilepsy Market in the US 2015-2019 Global
Ankylosing Spondylitis Market 2015-2019 Sickle-cel
l Anemia Therapeutics Market in the US
2015-2019 Global High-performance Thermoplastics
Market 2015-2019 Global Anxiety Disorders Market
2015-2019 Global Breast Imaging Market
2015-2019 Global Cancer Biomarkers Market
2015-2019 Global Fluid Treatment Market
2015-2019 Global Rapid Prototyping Equipment
Market 2015-2019 Healthcare RCM Outsourcing
Market in the US 2015-2019 Medical Technologies
Market in the APAC Region 2015-2019 Healthcare
Market Research Reports
10
f
Complete 2013-14 Induced Pluripotent Stem Cell
(iPSC) Industry Report Published Feb 2014 127
Pages Stem cell research and experimentation
has been in process for well over five decades,
as stem cells have the unique ability to divide
and replicate repeatedly. Price
Format Price
PDF 3495
Hard Copy 3545
Site License   4495
Enterprise Wide Licence 5495
11
f
Contact Us
  • You Can Visit http//www.aarkstore.com
  • OR Mail us at contact_at_aarkstore.com
  • Blog
  • http//www.aarkstore.com/blog/
  • Conference
  • http//conference.aarkstore.com/
  • News
  • http//www.aarkstore.com/news

Office Aarkstore Enterprise Office No. - 809,
8th Floor, B-Wing, Mahaavir Icon,  Plot No.- 89
90, Sector-15, CBD-Belapur, Navi Mumbai
400614,  Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 Partners contact 022-27564953
About PowerShow.com